judge Du's decision was explicit in that there should be no inducement to infringe on Amarin's R-IT patents...yet this is exactly what Hickma will be doing when it buys gV in large quantities(too large for the Marine indication)and sells it to Pharmacy Benefit Programs.
Drug Distributors could be liable for contributory infringement only, not for "inducement o[f] infringement" (unless they encourage the prescriber to infringe or promote the patented use ... not likely).
As MARINE indication is a "substantial non-infringing use" contributory infringement claim will not stand against anybody.
News 
Market Data 
Discover 
AI
